KAD-101 / Kaida BioPharma - LARVOL DELTA

Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer (GlobeNewswire) - "Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025."

New P1 trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Kaida BioPharma to Present at BioSparkVA Pitch Event (GlobeNewswire) - "Kaida BioPharma...announced that Craig Pierson, Chairman and Founder of Kaida BioPharma, will present at BioSparkVA's BioSpark Pitch Event, hosted by CVILLE Biohub and Cooley, taking place today, September 26, 2024 in Charlottesville, Virginia....The Company continues to progress the development of KAD101 toward the launch of its Phase 1 study, expected to commence in 2025. Additionally, the Company is advancing KAD102, an enhanced pure antagonist of KAD101, for the treatment of uterine cancer."

New P1 trial • Pipeline update • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer